178 related articles for article (PubMed ID: 34170386)
1. [Molecular tumor boards - insights and perspectives].
Laßmann S; Hummel M
Pathologe; 2021 Jul; 42(4):357-362. PubMed ID: 34170386
[TBL] [Abstract][Full Text] [Related]
2. Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
Willemsen AECAB; Krausz S; Ligtenberg MJL; Grünberg K; Groen HJM; Voest EE; Cuppen EPJG; van Laarhoven HWM; van Herpen CML
Br J Cancer; 2019 Jul; 121(1):34-36. PubMed ID: 31130724
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
[TBL] [Abstract][Full Text] [Related]
4. Molecular tumour boards - current and future considerations for precision oncology.
Tsimberidou AM; Kahle M; Vo HH; Baysal MA; Johnson A; Meric-Bernstam F
Nat Rev Clin Oncol; 2023 Dec; 20(12):843-863. PubMed ID: 37845306
[TBL] [Abstract][Full Text] [Related]
5. Molecular screening programs in different countries: what we learned and perspectives.
Borcoman E; Le Tourneau C; Kamal M
Curr Opin Oncol; 2019 Sep; 31(5):445-453. PubMed ID: 31261171
[TBL] [Abstract][Full Text] [Related]
6. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan.
Naito Y; Sunami K; Kage H; Komine K; Amano T; Imai M; Koyama T; Ennishi D; Kanai M; Kenmotsu H; Maeda T; Morita S; Sakai D; Watanabe K; Shirota H; Kinoshita I; Yoshioka M; Mamesaya N; Ito M; Kohsaka S; Saigusa Y; Yamamoto K; Hirata M; Tsuchihara K; Yoshino T
JAMA Netw Open; 2022 Dec; 5(12):e2245081. PubMed ID: 36469316
[TBL] [Abstract][Full Text] [Related]
7. Improving decision making in multidisciplinary tumor boards: prospective longitudinal evaluation of a multicomponent intervention for 1,421 patients.
Lamb BW; Green JS; Benn J; Brown KF; Vincent CA; Sevdalis N
J Am Coll Surg; 2013 Sep; 217(3):412-20. PubMed ID: 23891067
[TBL] [Abstract][Full Text] [Related]
8. Genomic expertise in action: molecular tumour boards and decision-making in precision oncology.
Bourret P; Cambrosio A
Sociol Health Illn; 2019 Nov; 41(8):1568-1584. PubMed ID: 31197873
[TBL] [Abstract][Full Text] [Related]
9. Integration of proteomics in the molecular tumor board.
Thiery J; Fahrner M
Proteomics; 2024 Jun; 24(12-13):e2300002. PubMed ID: 38143279
[TBL] [Abstract][Full Text] [Related]
10. A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence.
Sunami K; Naito Y; Saigusa Y; Amano T; Ennishi D; Imai M; Kage H; Kanai M; Kenmotsu H; Komine K; Koyama T; Maeda T; Morita S; Sakai D; Hirata M; Ito M; Kozuki T; Sakashita H; Horinouchi H; Okuma Y; Takashima A; Kubo T; Hironaka S; Segawa Y; Yakushijin Y; Bando H; Makiyama A; Suzuki T; Kinoshita I; Kohsaka S; Ohe Y; Ishioka C; Yamamoto K; Tsuchihara K; Yoshino T
JAMA Oncol; 2024 Jan; 10(1):95-102. PubMed ID: 38032680
[TBL] [Abstract][Full Text] [Related]
11. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
Ciliberto G; Canfora M; Terrenato I; Agnoletto C; Agustoni F; Amoroso L; Baldassarre G; Curigliano G; Delmonte A; De Luca A; Fiorentino M; Gregorc V; Ibrahim T; Lazzari C; Mastronuzzi A; Pronzato P; Santoro A; Scambia G; Tommasi S; Vingiani A; Giacomini P; De Maria R
J Exp Clin Cancer Res; 2022 Oct; 41(1):305. PubMed ID: 36245005
[TBL] [Abstract][Full Text] [Related]
12. Decision-Making in Multidisciplinary Tumor Boards in Breast Cancer Care - An Observational Study.
Schellenberger B; Diekmann A; Heuser C; Gambashidze N; Ernstmann N; Ansmann L
J Multidiscip Healthc; 2021; 14():1275-1284. PubMed ID: 34103928
[TBL] [Abstract][Full Text] [Related]
13. Molecular Tumor Boards in Clinical Practice.
Luchini C; Lawlor RT; Milella M; Scarpa A
Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
[TBL] [Abstract][Full Text] [Related]
14. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
15. Endorsing good quality assurance practices in molecular pathology: risks and recommendations for diagnostic laboratories and external quality assessment providers.
Tembuyser L; Dequeker EM
Virchows Arch; 2016 Jan; 468(1):31-41. PubMed ID: 26306715
[TBL] [Abstract][Full Text] [Related]
16. Patient attrition in Molecular Tumour Boards: a systematic review.
Frost H; Graham DM; Carter L; O'Regan P; Landers D; Freitas A
Br J Cancer; 2022 Nov; 127(8):1557-1564. PubMed ID: 35941175
[TBL] [Abstract][Full Text] [Related]
17. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures.
Engelhardt M; Ihorst G; Schumacher M; Rassner M; Gengenbach L; Möller M; Shoumariyeh K; Neubauer J; Farthmann J; Herget G; Wäsch R
BMC Cancer; 2021 Feb; 21(1):173. PubMed ID: 33596881
[TBL] [Abstract][Full Text] [Related]
19. The molecular tumor board: a tool for the governance of precision oncology in the real world.
Incorvaia L; Russo A; Cinieri S
Tumori; 2022 Aug; 108(4):288-290. PubMed ID: 34918610
[TBL] [Abstract][Full Text] [Related]
20. Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards.
Crimini E; Repetto M; Tarantino P; Ascione L; Antonarelli G; Rocco EG; Barberis M; Mazzarella L; Curigliano G
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
